Berkeley, CA – According to filings with the U.S. Securities and Exchange Commission, Correlia Biosystems is raising $9,574,826.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Akwasi Apori played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Correlia Biosystems

Measure proteins with unparalleled efficiency for data driven biology. Harness the power of microscale analysis. Correlia’s immunoassay tools use a proprietary gel technology to accelerate the molecular interactions that are fundamental to measuring proteins. Correlia’s platform is serving four of the world’s top 10 pharma companies (and counting!). We are a growing team of scientists and engineers with diverse expertise in engineering, biology, physics, and software. Team members come from UC Berkeley, MIT, Cornell, Laney, and other top schools. We value innovation, focus, caring for others, and hard work as we seek to expand the power of proteomics for data-driven biology. Immunoassays represent our first application but stay tuned for others.

To learn more about Correlia Biosystems, visit http://correliabio.com/

Contact:
Akwasi Apori, Chief Executive Officer
510-859-4577
https://www.linkedin.com/in/akwasi-apori-465b5211/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved